CS228591A3 - Pharmaceutical composition with a continuous liberation physiologically active component being stable in acid medium - Google Patents
Pharmaceutical composition with a continuous liberation physiologically active component being stable in acid medium Download PDFInfo
- Publication number
- CS228591A3 CS228591A3 CS912285A CS228591A CS228591A3 CS 228591 A3 CS228591 A3 CS 228591A3 CS 912285 A CS912285 A CS 912285A CS 228591 A CS228591 A CS 228591A CS 228591 A3 CS228591 A3 CS 228591A3
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- csf
- solution
- polypeptide
- pharmaceutical composition
- replaced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909016138A GB9016138D0 (en) | 1990-07-23 | 1990-07-23 | Continuous release pharmaceutical compositions |
GB909018416A GB9018416D0 (en) | 1990-08-23 | 1990-08-23 | Continuous release pharmaceutical compositions |
GB909018415A GB9018415D0 (en) | 1990-08-23 | 1990-08-23 | Continuous release pharmaceutical compositions |
GB909018418A GB9018418D0 (en) | 1990-08-23 | 1990-08-23 | Continuous release pharmaceutical compositions |
GB909018414A GB9018414D0 (en) | 1990-08-23 | 1990-08-23 | Continuous release pharmaceutical compositions |
GB909018417A GB9018417D0 (en) | 1990-08-23 | 1990-08-23 | Continuous release pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CS228591A3 true CS228591A3 (en) | 1992-03-18 |
Family
ID=27547094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS912285A CS228591A3 (en) | 1990-07-23 | 1991-07-22 | Pharmaceutical composition with a continuous liberation physiologically active component being stable in acid medium |
Country Status (18)
Country | Link |
---|---|
US (2) | US5320840A (fr) |
EP (1) | EP0473268B1 (fr) |
JP (1) | JP3188292B2 (fr) |
KR (1) | KR920002164A (fr) |
AT (1) | ATE251641T1 (fr) |
AU (1) | AU655187B2 (fr) |
BG (1) | BG94861A (fr) |
CA (1) | CA2047540A1 (fr) |
CS (1) | CS228591A3 (fr) |
DE (1) | DE69133324T2 (fr) |
FI (1) | FI913410A (fr) |
GB (1) | GB2246295B (fr) |
HU (1) | HUT60632A (fr) |
IE (1) | IE912365A1 (fr) |
IL (1) | IL98831A0 (fr) |
NZ (1) | NZ238889A (fr) |
PT (1) | PT98410A (fr) |
ZW (1) | ZW9391A1 (fr) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5718893A (en) * | 1984-04-15 | 1998-02-17 | Foster; Preston F. | Use of G-CSF to reduce acute rejection |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US6013853A (en) * | 1992-02-14 | 2000-01-11 | The University Of Texas System | Continuous release polymeric implant carrier |
US5876452A (en) * | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US20050181976A1 (en) * | 1993-05-10 | 2005-08-18 | Ekwuribe Nnochiri N. | Amphiphilic oligomers |
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
NZ260909A (en) * | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
IL110787A0 (en) * | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
DE69534676T2 (de) * | 1994-02-08 | 2006-08-17 | Amgen Inc., Thousand Oaks | Orale Verabreichung von chemisch modifizierten Proteinen |
JP4011106B2 (ja) * | 1994-02-23 | 2007-11-21 | 協和醗酵工業株式会社 | 血小板増殖促進剤 |
GEP20002180B (en) * | 1994-03-31 | 2000-07-25 | Amgen Inc | Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation |
US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
US5536495A (en) * | 1994-04-15 | 1996-07-16 | Foster; Preston F. | Use of G-CSF to reduce acute rejection |
JPH10506280A (ja) * | 1994-09-23 | 1998-06-23 | ディー. フィンケルスタイン,シドニー | 形態的遺伝子型識別法 |
US20030053982A1 (en) | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5576197A (en) * | 1995-04-07 | 1996-11-19 | Molecular Bio-Products | Polymerase chain reaction container and methods of using the same |
EP0832220A1 (fr) * | 1995-06-07 | 1998-04-01 | Amgen Inc. | Compositions renfermant la proteine ob et procedes associes |
FR2738827B1 (fr) * | 1995-09-18 | 1997-10-17 | Bio Merieux | Detection des enterobacteries |
US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
SI2319928T1 (sl) | 1998-10-23 | 2013-08-30 | Kirin-Amgen, Inc. | Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US6319510B1 (en) | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US6638906B1 (en) * | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
US6555660B2 (en) | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
ATE269716T1 (de) | 2000-02-29 | 2004-07-15 | Pfizer Prod Inc | Stabilisierter granulozyten-kolonie- stimulierender faktor |
US6716811B1 (en) | 2000-07-20 | 2004-04-06 | Affymax, Inc. | Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses |
US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
GB0022877D0 (en) * | 2000-09-18 | 2000-11-01 | Isis Innovation | Analogues |
ES2382636T3 (es) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
AU2001298061A1 (en) | 2000-12-13 | 2003-07-09 | Purdue Research Foundation | Microencapsulation of drugs by solvent exchange |
WO2002051428A1 (fr) * | 2000-12-25 | 2002-07-04 | Shiseido Company, Ltd. | Composition de parfum stimulant le systeme sympathique |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US7265186B2 (en) | 2001-01-19 | 2007-09-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
EP1425304B9 (fr) | 2001-07-11 | 2010-09-08 | Maxygen, Inc. | Conjugues de g-csf |
US6488952B1 (en) * | 2001-08-28 | 2002-12-03 | John P. Kennedy | Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system |
US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
KR100508358B1 (ko) | 2002-03-20 | 2005-08-17 | 주식회사 바이오폴리메드 | 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 g-csf의 제조 방법 |
US20030199464A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
SI21273A (sl) * | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
EP2426139B1 (fr) | 2002-08-27 | 2014-10-01 | Biokine Therapeutics Ltd. | Antagoniste CXCR4 et son utilisation |
EP1539960B1 (fr) * | 2002-09-09 | 2010-04-28 | Hanall Pharmaceutical Co., Ltd. | Polypeptides modifiés d'interferon alpha résistant aux protéases |
AU2003285200A1 (en) * | 2002-11-09 | 2004-06-03 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
BR0316560A (pt) * | 2002-11-26 | 2005-10-04 | Nobex Corp | Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto |
EP1613272B1 (fr) | 2003-04-11 | 2013-12-18 | Antriabio, Inc. | Procede de preparation de conjugues de proteines specifiques de site |
JP4829783B2 (ja) * | 2003-06-24 | 2011-12-07 | バイオコン・リミテッド | カルシトニン薬−オリゴマーコンジュゲートの混合物および疼痛治療における使用方法 |
CA2536152A1 (fr) * | 2003-08-22 | 2005-03-03 | The Council Of The Queensland Institute Of Medical Research | Derive de g-csf utilise pour induire une tolerance immunologique |
US8338373B2 (en) | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
ATE544460T1 (de) * | 2003-10-24 | 2012-02-15 | Nora Therapeutics Inc | Zusammensetzungen und verfahren für eine gesunde schwangerschaft |
US20090226397A1 (en) * | 2003-10-24 | 2009-09-10 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
US7220407B2 (en) | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
NZ548529A (en) * | 2003-12-16 | 2010-08-27 | Nektar Therapeutics | Pegylated small molecules |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
JP2008505928A (ja) | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
CA2580313C (fr) * | 2004-07-19 | 2016-03-15 | Biocon Limited | Conjugues insuline-oligomere, preparations et utilisations de ceux-ci |
WO2009100255A2 (fr) | 2008-02-08 | 2009-08-13 | Ambrx, Inc. | Polypeptides leptine modifiés et leurs utilisations |
EP1812601A2 (fr) * | 2004-10-22 | 2007-08-01 | Redpath Integrated Pathology, Inc. | Expansion dynamique des suppressions genomiques et formulation de jeux de marqueurs moleculaires pour diagnostic integre de pathologie moleculaire et caracterisation des echantillons de tissus, de fluides cellulaires et de fluides purs |
WO2006055260A2 (fr) | 2004-11-05 | 2006-05-26 | Northwestern University | Utilisation de scf et de scf dans le traitement de l'ischemie cerebrale et des troubles neurologiques |
WO2006076471A2 (fr) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Conjugues bnp et procedes d'utilisation |
TW200640492A (en) * | 2005-02-21 | 2006-12-01 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
BRPI0611221A2 (pt) | 2005-06-01 | 2010-08-24 | Maxygen Holdings Ltd | polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos |
ATE524509T1 (de) | 2005-07-18 | 2011-09-15 | Nektar Therapeutics | Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen |
CA2616230A1 (fr) * | 2005-07-22 | 2007-02-01 | Trf Pharma, Inc. | Methode destinee a traiter la drepanocytose et les sequelles de la drepanocytose |
WO2007084460A2 (fr) * | 2006-01-18 | 2007-07-26 | Qps, Llc | Compositions pharmaceutiques a stabilite amelioree |
US7678838B2 (en) * | 2006-08-04 | 2010-03-16 | University Of Memphis Research Foundation | Nanothin polymer films with selective pores and method of use thereof |
US7829155B1 (en) | 2006-11-22 | 2010-11-09 | The University Of Memphis Research Foundation | Nanothin polymer coatings containing thiol and methods of use thereof |
FR2909560B1 (fr) * | 2006-12-06 | 2012-12-28 | Fabre Pierre Dermo Cosmetique | Gel d'acide hyaluronique pour injection intradermique |
WO2008075370A2 (fr) | 2006-12-21 | 2008-06-26 | Biokine Therapeutics Ltd. | Analogues peptidiques de t-140 présentant une activité superagoniste par rapport à cxcr4 destinés à une cancérothérapie |
JP5868594B2 (ja) | 2007-10-16 | 2016-02-24 | バイオコン・リミテッドBiocon Limited | 経口投与可能な固形医薬組成物及びそのプロセス |
US20110171168A1 (en) * | 2008-05-13 | 2011-07-14 | Nora Therapeutics, Inc. | Human g-csf analogs and methods of making and using thereof |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
WO2010079340A2 (fr) | 2009-01-08 | 2010-07-15 | Eisai R & D Management Co., Ltd. | Dosage |
EP2396023A2 (fr) | 2009-02-11 | 2011-12-21 | Yeda Research and Development Co. Ltd. | Peptides courts dérivés de bêta-défensine |
US9427456B2 (en) | 2009-06-14 | 2016-08-30 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
KR20120099371A (ko) | 2009-08-05 | 2012-09-10 | 피어이스 에이지 | 리포칼린 뮤테인의 조절 방출 제형 |
AU2010341516B2 (en) | 2009-12-21 | 2014-01-16 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
GB0922438D0 (en) | 2009-12-22 | 2010-02-03 | Ucl Business Plc | Agents having tissue generative activity |
KR101857825B1 (ko) | 2010-03-04 | 2018-05-14 | 피페넥스 인크. | 변성 없이 가용성 재조합 인터페론 단백질을 제조하는 방법 |
WO2011123570A2 (fr) | 2010-04-01 | 2011-10-06 | Pfenex Inc. | Procédés pour la production de g-csf dans une cellule hôte de pseudomonas |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
WO2012065086A1 (fr) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugués d'une fraction il-2 et d'un polymère |
US8440309B2 (en) | 2011-01-31 | 2013-05-14 | Confluent Surgical, Inc. | Crosslinked polymers with the crosslinker as therapeutic for sustained release |
EP2841084B1 (fr) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Peptide antagoniste de cxcr4 et son utilisation pour le traitment de tumeurs pulmonaires |
US9341628B2 (en) | 2012-11-30 | 2016-05-17 | Interpace Diagnostics Corporation | Methods for measuring carcinoembryonic antigen |
WO2015057724A1 (fr) | 2013-10-14 | 2015-04-23 | Nora Therapeutics, Inc. | Utilisation de g-csf pour traiter ou prévenir la villite d'étiologie indéterminée chez une femme |
CA2986705A1 (fr) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Inhibiteur de cxcr4 et antagoniste de proteine disulfure isomerase a utiliser dans le traitement du cancer |
EP3341025A4 (fr) * | 2015-09-24 | 2019-05-01 | Hanmi Pharm. Co., Ltd. | Complexe de protéines au moyen d'un site spécifique d'un fragment d'immunoglobuline pour liaison |
KR101763644B1 (ko) * | 2015-12-03 | 2017-08-02 | 윤안구 | 폐 생리대 수거함 |
JP6676182B2 (ja) | 2016-02-23 | 2020-04-08 | バイオラインアールエックス・リミテッドBioLineRx Ltd. | 急性骨髄性白血病の治療方法 |
WO2018138267A1 (fr) | 2017-01-27 | 2018-08-02 | Cinfa Biotech S.L. | Procede de determination de l'efficacite d'une composition comprenant le g-csf |
US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
US10758329B1 (en) | 2019-08-20 | 2020-09-01 | Raymond L. Wright, III | Hydrating mouth guard |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6812443A (fr) * | 1968-08-31 | 1970-03-03 | ||
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4414147A (en) * | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
DE3378250D1 (en) * | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
EP0098110B1 (fr) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Composition à action prolongée |
DE3572982D1 (en) * | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
DE3676670D1 (de) * | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US4818769A (en) * | 1985-09-20 | 1989-04-04 | Cetus Corporation | Method of controlling stress-related disease in livestock by administration of human IL-2 |
JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
DE68907066T2 (de) * | 1988-01-29 | 1993-12-16 | Sumitomo Pharma | Verbesserte Formulierungen mit kontrollierter Abgabe. |
CA1340810C (fr) * | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Derives de polypeptides actifs comme facteurs stimulant les colonies de granulocytes chez l'homme |
FR2630329B1 (fr) * | 1988-04-20 | 1991-07-05 | Merieux Inst | Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
CA2006596C (fr) * | 1988-12-22 | 2000-09-05 | Rika Ishikawa | G-csf modifie chimiquement |
US5055555A (en) * | 1989-01-05 | 1991-10-08 | Helmut Sassenfeld | Purification of G-CSF |
GB9107846D0 (en) * | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
-
1991
- 1991-07-05 IE IE236591A patent/IE912365A1/en unknown
- 1991-07-09 NZ NZ238889A patent/NZ238889A/en unknown
- 1991-07-15 FI FI913410A patent/FI913410A/fi unknown
- 1991-07-15 IL IL98831A patent/IL98831A0/xx unknown
- 1991-07-15 GB GB9115207A patent/GB2246295B/en not_active Expired - Lifetime
- 1991-07-15 ZW ZW93/91A patent/ZW9391A1/xx unknown
- 1991-07-16 EP EP91306452A patent/EP0473268B1/fr not_active Expired - Lifetime
- 1991-07-16 DE DE69133324T patent/DE69133324T2/de not_active Expired - Lifetime
- 1991-07-16 AT AT91306452T patent/ATE251641T1/de not_active IP Right Cessation
- 1991-07-19 BG BG94861A patent/BG94861A/xx unknown
- 1991-07-22 US US07/734,225 patent/US5320840A/en not_active Expired - Lifetime
- 1991-07-22 HU HU912442A patent/HUT60632A/hu unknown
- 1991-07-22 CS CS912285A patent/CS228591A3/cs unknown
- 1991-07-22 JP JP27174391A patent/JP3188292B2/ja not_active Expired - Lifetime
- 1991-07-22 AU AU81238/91A patent/AU655187B2/en not_active Ceased
- 1991-07-22 CA CA002047540A patent/CA2047540A1/fr not_active Abandoned
- 1991-07-22 PT PT98410A patent/PT98410A/pt not_active Application Discontinuation
- 1991-07-22 KR KR1019910012589A patent/KR920002164A/ko not_active Application Discontinuation
-
1995
- 1995-06-07 US US08/488,457 patent/US5773581A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
GB2246295A (en) | 1992-01-29 |
EP0473268B1 (fr) | 2003-10-08 |
GB9115207D0 (en) | 1991-08-28 |
EP0473268A3 (en) | 1992-09-16 |
ATE251641T1 (de) | 2003-10-15 |
HUT60632A (en) | 1992-10-28 |
BG94861A (en) | 1994-03-24 |
HU912442D0 (en) | 1991-12-30 |
KR920002164A (ko) | 1992-02-28 |
IL98831A0 (en) | 1992-07-15 |
US5320840A (en) | 1994-06-14 |
NZ238889A (en) | 1993-08-26 |
AU8123891A (en) | 1992-01-30 |
PT98410A (pt) | 1992-06-30 |
AU655187B2 (en) | 1994-12-08 |
US5773581A (en) | 1998-06-30 |
GB2246295B (en) | 1994-05-11 |
FI913410A0 (fi) | 1991-07-15 |
DE69133324T2 (de) | 2004-07-29 |
CA2047540A1 (fr) | 1992-01-24 |
JP3188292B2 (ja) | 2001-07-16 |
JPH0532559A (ja) | 1993-02-09 |
DE69133324D1 (de) | 2003-11-13 |
ZW9391A1 (en) | 1992-03-25 |
EP0473268A2 (fr) | 1992-03-04 |
FI913410A (fi) | 1992-01-24 |
IE912365A1 (en) | 1992-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS228591A3 (en) | Pharmaceutical composition with a continuous liberation physiologically active component being stable in acid medium | |
AU644647B2 (en) | Polypeptides | |
EP0088540A2 (fr) | Séquences d'ADN, molécules d'ADN recombinant et procédure pour la production de polypeptides semblables à l'interféron humain immun | |
AU629176B2 (en) | Recombinant fibroblast growth factors | |
EP0425482B1 (fr) | Analogues d'insuline humaine et preparations les contenant | |
US5004689A (en) | DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields | |
FI100972B (fi) | Pesäkkeitä stimuloivaa tekijä-1:tä (CSF-1) koodaava DNA-sekvenssi ja m enetelmä CSF-1-proteiinin valmistamiseksi | |
HU202287B (en) | Process for producing human immune interferon | |
IE66689B1 (en) | Recombinant fibroblast growth factors | |
EP0118977A1 (fr) | Séquences d'ADN, molécules recombinantes d'ADN et procédés pour la production des polypeptides semblables à interleukin-2 humain | |
DK174598B1 (da) | Glycosyleret eller ikke glycosyleret rekombinant polypeptid med aktivitet som human granulocyt/makrofag og eosinofil cellevækstfaktor, fremgangsmåde til fremstilling af polypeptidet, nucleotidsekvens kodende for polypeptidet, ..... | |
CA2232264C (fr) | Variants de .gamma.-interferon recombinant humain (rhu-ifn-.gamma.) ayant une stabilite thermique accrue | |
AU627477B2 (en) | Interleukin ii analogs | |
EP0811064B1 (fr) | Analogues de ligand mpl | |
AU727978B2 (en) | MPL ligand analogs | |
CN101245109B (zh) | 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法 | |
JP3288373B2 (ja) | 安定および生体活性改変ソマトトロピン類 | |
WO2002081519A9 (fr) | Nouvelle proteine hybride ifn-thy, preparation et utilisation | |
Otto et al. | Expression of recombinant feline tumor necrosis factor is toxic to Escherichia coli | |
AU599891B2 (en) | CDNA clones coding for polypeptides exhibiting murine interleukin-2 activity | |
CZ443885A3 (en) | Dna sequence used for assuring expression of polypeptide product | |
HU204086B (en) | Process for producing non-human mammal animal interferons, dna sequemces coding form them and pharmaceutical compositions comprising sand interferons | |
IE66691B1 (en) | Human insulin analoga and preparations containing them |